

Insights into the personal experience of migraine patients and the positive impact on their quality of life during erenumab treatment



Scan to download a copy of this presentation

Katrin Schuh, Mirja Koch*¹, Heike Israel-Willner², Charly Gaul³

¹Clinical Research Neuroscience, Novartis Pharma GmbH, Nuremberg, ²NFZB, Specialized Center of Neurology Berlin, Berlin, Germany; ³Migraine and Headache Clinic, Koenigstein am Taunus, Germany

Migraine Trust Virtual Symposium, 3–9 October, 2020

This study is supported by Novartis Pharma GmbH, Germany. Erenumab is co-developed by Amgen and Novartis.


Parts of this data were previously presented at 72st Annual Meeting of American Academy of Neurology, April 25–May 1, 2020

Background and Results



- 29,042 patients suffering from migraine completed an online survey (PERISCOPE) between July and December 2019 on their migraine history and their experience with pharmacological and non-pharmacological therapies
- Among the participants, 155 patients were undergoing erenumab treatment and were asked to provide insights into their perception of therapeutic outcomes

Figure 1. Prior and current prophylactic treatments of migraine patients



- 67.5% of all patients did not receive prophylactic treatment when completing the questionnaire (n=19,334)
- Less than 1% of the patients received monoclonal antibody-based therapies



- Monthly migraine days (MMD) and days with acute medication use were substantially reduced after three months of erenumab treatment (n=115)
- 45.7% of patients reported onset of therapeutic effect already after first injection (n=129)

Figure 2. Erenumab improves migraine specific key parameters in the first three months








Figure 3. Improvements in migraine symptoms and therapy recommendation



- PERISCOPE provides us with first **real-world evidence** data for erenumab in Germany **from the patients' perspective**
- After three months of therapy, erenumab had a meaningful impact on MMD
- Also patients considered as non-responders reported benefits from erenumab treatment
- Overall, the analysis shows that in real-world, erenumab patients experience and report benefits in various key migraine parameters